Health & Fitness
Health and Fitness
Health and Fitness 
Wed, March 27, 2013
Tue, March 26, 2013
Mon, March 25, 2013
Sun, March 24, 2013
Fri, March 22, 2013
Thu, March 21, 2013
Wed, March 20, 2013
Tue, March 19, 2013
Mon, March 18, 2013
Sun, March 17, 2013
Fri, March 15, 2013
Thu, March 14, 2013
Wed, March 13, 2013
Tue, March 12, 2013
Mon, March 11, 2013
Sun, March 10, 2013
Sat, March 9, 2013
Fri, March 8, 2013
Thu, March 7, 2013
Wed, March 6, 2013
Tue, March 5, 2013
Mon, March 4, 2013
Sun, March 3, 2013
Sat, March 2, 2013
Fri, March 1, 2013
Depomed To Present At Roth Capital Partners 25th Annual Growth Stock Conference
Depomed To Present At Roth Capital Partners 25th Annual Growth Stock Conference -- NEWARK, Calif., March 13, 2013 /PRNewswire/ --
NEWARK, Calif., March 13, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: [ DEPO ]) today announced that it will be presenting at the Roth Capital Partners 25th Annual Growth Stock Conference at the Ritz-Carlton Hotel in Dana Point, California.
The presentation at the Roth conference is scheduled for 11:30 am PDT (2:30 pm EDT) on Tuesday March 19, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at [ www.depomed.com ]. A recording of the webcast will be archived for 30 days on the company's website.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with three approved and marketed products. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Zipsor ®(diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, [ www.depomed.com ].
CONTACT:
August J. Moretti
Depomed, Inc. 510.744.8000
SOURCE Depomed, Inc.
RELATED LINKS
[ http://www.depomed.com ]
